Using cell viability assays, we confirmed the potent activity against EML4-ALK fusion gene (WT, v1, and v3)-positive NSCLC cells (H3122 and H2228 cells) and patient-derived primary cancer cells (JFCR-028-3 and JFCR-018-1) (Fig. 2a and Supplementary Table 3A). Here, EML4 is linked to cancer.